Skip to main content
. 2022 Mar 28;28:366–386. doi: 10.1016/j.omtn.2022.03.020

Figure 4.

Figure 4

miR-6077 protects LUAD cells from CDDP/PEM-induced cell-cycle arrest by directly targeting CDKN1A

(A) Quantitative real-time PCR assay confirming the ectopic overexpression of CDKN1A in A549 cells. (B) Dose-toxicity curves showing the viability of A549 cells (with or without CDKN1A overexpression) transfected with miR-NC1, miR-NC2, and miR-6077 upon CDDP/PEM treatment at the indicated concentrations for 48 h. (C–E) Colony formation ability (C), cell-cycle proportion (D), and protein levels of CDKN1A and its downstream cell-cycle regulators (E) in A549 cells (with or without CDKN1A overexpression) transfected with miR-NC1, miR-NC2, and miR-6077 upon treatment with PBS or CDDP (10 μM)/PEM (1 μM) for 14 days (C) or 48 h (D and E). (F) Dose-toxicity curves showing the viability of A549 cells (with or without CDKN1A overexpression) transfected with miR-NC1, miR-NC2, and miR-6077 upon treatment with PEM and oxaliplatin or carboplatin at the indicated concentrations for 48 h. Data are presented as the mean ± SD, n = 3 independent repeats. Unpaired, two-tailed t test; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; ns, not significant.